Table. Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) Overall Treatment Satisfaction and Subscale Scores at Week 40a.
| Scale | PDS with ranibizumab, 100 mg/mL every 24 wk | Intravitreal ranibizumab, 0.5 mg every 4 wk | Difference (95% CI) | ||
|---|---|---|---|---|---|
| No. | Mean (95% CI) | No. | Mean (95% CI) | ||
| Overall treatment satisfaction scoreb | 237 | 68.0 (67.4-68.6) | 159 | 66.1 (64.9-67.3) | 1.9 (0.7 to 3.1) |
| Treatment convenience, information provision, and general satisfaction subscale scorec | 228 | 34.7 (34.4-34.9) | 155 | 34.1 (33.6-34.7) | 0.6 (–0.1 to 1.2) |
| Impact of treatment subscale scorec | 237 | 33.4 (32.9-33.8) | 159 | 32.0 (31.2-32.7) | 1.4 (0.6 to 2.2) |
Abbreviation: PDS, port delivery system with ranibizumab.
a
Treatment group means, differences, and associated 95% CIs were estimated with an analysis of variance model with randomized treatment as the independent variable.
b
The overall MacTSQ score is on a scale of 1 to 72, with scores of at least 60 indicating high satisfaction.
c
Each MacTSQ subscale is on a scale of 1 to 36, with scores of at least 30 indicating high satisfaction.